These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 21312399)

  • 1. Antipsychotic drug development.
    Kim DH; Stahl SM
    Curr Top Behav Neurosci; 2010; 4():123-39. PubMed ID: 21312399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia.
    Kim DH; Maneen MJ; Stahl SM
    Neurotherapeutics; 2009 Jan; 6(1):78-85. PubMed ID: 19110200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006 Sep; 67(9):e11. PubMed ID: 17081078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular targets for treating cognitive dysfunction in schizophrenia.
    Gray JA; Roth BL
    Schizophr Bull; 2007 Sep; 33(5):1100-19. PubMed ID: 17617664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes.
    Joyce JN; Goldsmith SG; Gurevich EV
    J Psychiatr Res; 1997; 31(2):197-217. PubMed ID: 9278186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia.
    Kasper S; Tauscher J; Küfferle B; Barnas C; Pezawas L; Quiner S
    Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 4():83-9. PubMed ID: 10654113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (D1, D3, D4) and 5-HT2a receptors.
    Harrison PJ
    Br J Psychiatry Suppl; 1999; (38):12-22. PubMed ID: 10884896
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel targets for drugs in schizophrenia.
    Stone JM; Pilowsky LS
    CNS Neurol Disord Drug Targets; 2007 Aug; 6(4):265-72. PubMed ID: 17691983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights into the biology of schizophrenia through the mechanism of action of clozapine.
    Brunello N; Masotto C; Steardo L; Markstein R; Racagni G
    Neuropsychopharmacology; 1995 Nov; 13(3):177-213. PubMed ID: 8602893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current concepts of the effects of neuroleptics].
    Kostowski W; Płaźnik A
    Psychiatr Pol; 1990; 24(5):28-37. PubMed ID: 1983397
    [No Abstract]   [Full Text] [Related]  

  • 12. Need for a new framework to understand the mechanism of all antipsychotics.
    Stip E; Liddle PF; Soucy JP
    J Clin Psychiatry; 2000 May; 61(5):387-8. PubMed ID: 10847316
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia.
    Deutch AY; Moghaddam B; Innis RB; Krystal JH; Aghajanian GK; Bunney BS; Charney DS
    Schizophr Res; 1991; 4(2):121-56. PubMed ID: 1674882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006; 67 Suppl 9():9-13; discussion 36-42. PubMed ID: 16965183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness.
    Breese GR; Knapp DJ; Moy SS
    Neurosci Biobehav Rev; 2002 Jun; 26(4):441-55. PubMed ID: 12204191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine receptors, antipsychotic action and schizophrenia.
    Reynolds GP
    J Psychopharmacol; 1999; 13(2):202-3. PubMed ID: 10475731
    [No Abstract]   [Full Text] [Related]  

  • 17. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
    Miyamoto S; Duncan GE; Marx CE; Lieberman JA
    Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo neuropharmacology of schizophrenia.
    Bigliani V; Pilowsky LS
    Br J Psychiatry Suppl; 1999; (38):23-33. PubMed ID: 10884897
    [No Abstract]   [Full Text] [Related]  

  • 20. Dopamine receptor pharmacology: interactions with serotonin receptors and significance for the aetiology and treatment of schizophrenia.
    Werkman TR; Glennon JC; Wadman WJ; McCreary AC
    CNS Neurol Disord Drug Targets; 2006 Feb; 5(1):3-23. PubMed ID: 16613551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.